Table 3.
Changes of nausea grade and nausea control rate after receiving olanzapine combined with standard antiemetic therapy.
| Acute phase (0–24 h) | Delayed phase (24–120 h) | Overall phase (0–120 h) | ||||
|---|---|---|---|---|---|---|
| Without OLN | With OLN | Without OLN | With OLN | Without OLN | With OLN | |
| Nausea grade | ||||||
| 0 | 17 (34%) | 43 (86%) | 0 (0%) | 21 (42%) | 0 (0%) | 20 (40%) |
| 1 | 12 (24%) | 6 (12%) | 1 (2%) | 26 (52%) | 0 (0%) | 26 (52%) |
| 2 | 14 (28%) | 1 (2%) | 20 (40%) | 3 (6%) | 18 (36%) | 4 (8%) |
| 3 | 7 (14%) | 0 (0%) | 29 (58%) | 0 (0%) | 32 (64%) | 0 (0%) |
|
| ||||||
| Nausea control rate* | 58% | 98% | 2% | 94% | 0% | 92% |
|
| ||||||
| P value** | P < 0.001 | P < 0.001 | P < 0.001 | |||
OLN: olanzapine, *nausea grade 0 or 1 (CTCAE ver. 4.0), and **McNemar test.